Frankel David S, Meigs James B, Massaro Joseph M, Wilson Peter W F, O'Donnell Christopher J, D'Agostino Ralph B, Tofler Geoffrey H
Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Circulation. 2008 Dec 9;118(24):2533-9. doi: 10.1161/CIRCULATIONAHA.108.792986. Epub 2008 Nov 24.
Von Willebrand factor (vWF) is inconsistently associated with cardiovascular disease (CVD). This might be explained by associations of vWF with type 2 diabetes mellitus and insulin resistance.
We tested whether vWF predicted incident CVD in 3799 Framingham Offspring Study participants, and in particular, among those with type 2 diabetes mellitus or insulin resistance. During 11 years of follow-up, 351 participants developed CVD. In proportional hazards models (with adjustment for age, sex, blood pressure, smoking, body mass index, total and high-density lipoprotein cholesterol, and treatment with aspirin, insulin, antihypertensives, and lipid-lowering medications) with the lowest quartile of the vWF distribution as the referent, the hazard ratio (HR) for CVD was 0.94 in the second quartile, 0.98 in the third, and 1.32 in the highest (P=0.04 for trend). Additional adjustment for type 2 diabetes mellitus or insulin resistance (homeostasis model) partially attenuated the association (multivariable HRs for top quartile 1.28 and 1.21, respectively). We then stratified the models by diabetes status or the homeostasis model of insulin resistance distribution (top quartile versus lower 3 quartiles). vWF was associated with CVD among participants with diabetes mellitus (HR for top quartile relative to bottom 1.47, P=0.04 for trend) but not among nondiabetic participants (HR 1.15, P=0.5) and similarly among insulin-resistant (HR 1.50, P=0.01) but not insulin-sensitive (HR 1.02, P=0.9) participants.
Higher levels of vWF were associated with risk of CVD in people with type 2 diabetes mellitus or insulin resistance, which suggests that vWF may be a risk factor unique to these populations.
血管性血友病因子(vWF)与心血管疾病(CVD)的关联并不一致。这可能是由于vWF与2型糖尿病和胰岛素抵抗有关。
我们在3799名弗雷明汉心脏研究后代参与者中,特别是在那些患有2型糖尿病或胰岛素抵抗的参与者中,测试了vWF是否能预测CVD的发生。在11年的随访期间,351名参与者发生了CVD。在比例风险模型中(对年龄、性别、血压、吸烟、体重指数、总胆固醇和高密度脂蛋白胆固醇以及使用阿司匹林、胰岛素、抗高血压药和降脂药物进行调整),以vWF分布的最低四分位数作为参照,CVD的风险比(HR)在第二个四分位数中为0.94,在第三个四分位数中为0.98,在最高四分位数中为1.32(趋势P=0.04)。对2型糖尿病或胰岛素抵抗(稳态模型)进行额外调整后,这种关联部分减弱(最高四分位数的多变量HR分别为1.28和1.21)。然后,我们根据糖尿病状态或胰岛素抵抗分布的稳态模型(最高四分位数与较低的三个四分位数)对模型进行分层。vWF与糖尿病参与者中的CVD相关(最高四分位数相对于最低四分位数的HR为1.47,趋势P=0.04),但在非糖尿病参与者中不相关(HR为1.15,P=0.5),在胰岛素抵抗参与者中(HR为1.50,P=0.01)也是如此,但在胰岛素敏感参与者中不相关(HR为1.02,P=0.9)。
较高水平的vWF与2型糖尿病或胰岛素抵抗患者的CVD风险相关,这表明vWF可能是这些人群特有的危险因素。